UBS Group’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-190
| Closed | -$1.31K | – | 10597 |
|
|
2025
Q4 | $1.31K | Buy |
+190
| New | +$1.26K | ﹤0.01% | 9634 |
|
|
2025
Q2 | – | Sell |
-529
| Closed | -$4.59K | – | 10327 |
|
|
2025
Q1 | $4.59K | Buy |
+529
| New | +$5.36K | ﹤0.01% | 9089 |
|
|
2024
Q4 | – | Sell |
-1,279
| Closed | -$6.23K | – | 9996 |
|
|
2024
Q3 | $6.23K | Buy |
1,279
+900
| +237% | +$4.22K | ﹤0.01% | 7987 |
|
|
2024
Q2 | $1.96K | Sell |
379
-728
| -66% | -$3.55K | ﹤0.01% | 8455 |
|
|
2024
Q1 | $5.42K | Sell |
1,107
-1,122
| -50% | -$6.57K | ﹤0.01% | 7543 |
|
|
2023
Q4 | $12.5K | Sell |
2,229
-897
| -29% | -$5K | ﹤0.01% | 7346 |
|
|
2023
Q3 | $19.4K | Buy |
+3,126
| New | +$19.8K | ﹤0.01% | 6822 |
|
|
2022
Q3 | – | Sell |
-2,000
| Closed | -$16K | – | 10417 |
|
|
2022
Q2 | $16K | Sell |
2,000
-1,022
| -34% | -$7.82K | ﹤0.01% | 7184 |
|
|
2022
Q1 | $24K | Buy |
3,022
+2,742
| +979% | +$22K | ﹤0.01% | 7236 |
|
|
2021
Q4 | $2K | Buy |
+280
| New | +$2.58K | ﹤0.01% | 9785 |
|
|
2021
Q3 | – | Sell |
-76
| Closed | -$1K | – | 9609 |
|
|
2021
Q2 | $1K | Sell |
76
-2,477
| -97% | -$25.1K | ﹤0.01% | 9137 |
|
|
2021
Q1 | $29K | Buy |
2,553
+1,592
| +166% | +$18.5K | ﹤0.01% | 7036 |
|
|
2020
Q4 | $10K | Sell |
961
-730
| -43% | -$7.53K | ﹤0.01% | 7476 |
|
|
2020
Q3 | $16K | Sell |
1,691
-1,561
| -48% | -$13.9K | ﹤0.01% | 6465 |
|
|
2020
Q2 | $31K | Buy |
+3,252
| New | +$27.7K | ﹤0.01% | 6242 |
|
|
2020
Q1 | – | Sell |
-1,398
| Closed | -$12K | – | 8018 |
|
|
2019
Q4 | $12K | Buy |
+1,398
| New | +$8.63K | ﹤0.01% | 7178 |
|
|
2019
Q3 | – | Sell |
-225
| Closed | -$2K | – | 8027 |
|
|
2019
Q2 | $2K | Buy |
+225
| New | +$1.97K | ﹤0.01% | 7607 |
|
|
2019
Q1 | – | Sell |
-368
| Closed | -$3K | – | 7776 |
|
|
2018
Q4 | $3K | Sell |
368
-4,312
| -92% | -$49.5K | ﹤0.01% | 7709 |
|
|
2018
Q3 | $82K | Buy |
4,680
+3,090
| +194% | +$27.5K | ﹤0.01% | 5754 |
|
|
2018
Q2 | $10K | Buy |
1,590
+636
| +67% | +$3.06K | ﹤0.01% | 7123 |
|
|
2018
Q1 | $3K | Buy |
+954
| New | +$3.56K | ﹤0.01% | 7411 |
|
|
2017
Q3 | – | Sell |
-5,490
| Closed | -$14K | – | 7751 |
|
|
2017
Q2 | $14K | Buy |
5,490
+1,223
| +29% | +$3.19K | ﹤0.01% | 6536 |
|
|
2017
Q1 | $14K | Buy |
4,267
+4,170
| +4,299% | +$14.6K | ﹤0.01% | 6396 |
|
|
2016
Q4 | $0 | Sell |
97
-1,103
| -92% | -$2.15K | ﹤0.01% | 7797 |
|
|
2016
Q3 | $2K | Sell |
1,200
-422
| -26% | -$785 | ﹤0.01% | 7396 |
|
|
2016
Q2 | $3K | Buy |
+1,622
| New | +$5.07K | ﹤0.01% | 7318 |
|
|
2016
Q1 | – | Sell |
-786
| Closed | -$3K | – | 7702 |
|
|
2015
Q4 | $3K | Buy |
786
+303
| +63% | +$1.3K | ﹤0.01% | 7867 |
|
|
2015
Q3 | $3K | Buy |
+483
| New | +$3.15K | ﹤0.01% | 7929 |
|
Other funds holding CSBR
BMC
NMC
TAM
VCM
MBAM
UBS Group's CSBR Position: Q1 2026 in Review
UBS Group sold out of Champions Oncology (CSBR) in Q1 2026, closing a stake of 190 shares — an estimated $1.31K sold.
UBS Group first reported a position in CSBR in Q3 2015 and held it in 28 quarters. The position peaked at $82K in Q3 2018. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2026.
- UBS Group reported no remaining Champions Oncology position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 190 Champions Oncology shares in Q1 2026, an estimated $1.31K.
- UBS Group first reported a position in Champions Oncology in Q3 2015 and held it in 28 quarters.
- UBS Group's Champions Oncology position peaked at $82K in Q3 2018.
- 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.